Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

Share Price is delayed by 15 minutes
Get Live Data
13.50    0.00 (0.00%)
Bid:
13.25
Ask:
13.75
Spread: 0.50 (3.774%)
Market Cap: £65.58m
CREO Live PriceLast checked at - London Stock Exchange

Intraday Creo Medical Share Chart

Completion of Acquisitions

8 Aug 2007 07:00

China Real Estate Opportunities Ltd08 August 2007 CHINA REAL ESTATE OPPORTUNITIES LIMITED Completion of Acquisitions, Publication of Circular, Notice of EGM and appointments at Treasury Holdings China Completion of Acquisitions In its admission document published on 10 July 2007, China Real EstateOpportunities Limited ("CREO" or "the Company") referred to agreements it hadentered into to acquire the City Centre and Central Plaza properties in Shanghaias key components of its initial portfolio. The Company is pleased to announcethat the acquisition of these properties has now been completed. City Centre has been acquired for £274,799,860, with financing provided byCredit Suisse, and Central Plaza has been acquired for £72,838,517, withfinancing provided by AAReal Bank. City Centre consists of a retail and officecomplex in the Hongqiao district of Shanghai, with an existing gross floor areaof some 187,650 square metres, and a site on which the company plans toconstruct a mixed-use development of some 77,500 square metres. Central Plaza isa 19-storey office building overlooking People's Square in Shanghai having agross floor area of 47,247 square metres. Circular The Company will today distribute a circular to shareholders together with anotice of Extraordinary General Meeting to be held on 3 September 2007. Thepurpose of this circular is to seek shareholders' authority to enable theCompany to make market purchases of its own shares and, in order to facilitatethis, to approve the requisite waiver by the Panel on Takeovers and Mergersunder Rule 9 of the City of Code on Takeovers and Mergers (the "Rule 9 Waiver"). In the period since the Company's shares were admitted to AIM, market conditionsfor equities providing exposure to property markets both in the UK and elsewherehave deteriorated markedly. In the circumstances, the Board believes that itwould be in the interests of shareholders as a whole for the Company to have theflexibility to stand in the market place as a potential purchaser of its ownshares. The Directors, advised by Teather & Greenwood, are recommending shareholders tovote in favour of the resolution to purchase its own shares and the IndependentDirectors, advised by Teather & Greenwood, are recommending shareholders to votein favour of the resolution to approve the Rule 9 Waiver. Appointments CREO also announces the appointments of Richard David and Richard Ding to thepositions of Managing Director and General Counsel of Treasury Holdings China("THC") respectively. THC is CREO's investment manager with responsibility formanaging its existing property portfolio, sourcing additional real estateinvestments and making investment decisions, subject to overall supervision bythe Board of Directors of CREO. Richard David has joined THC from Macquarie Bank Limited, where he was managingdirector of Macquarie Real Estate Capital China. Richard has since 1999 overseenthe operations of Macquarie China, including several business units operatingwithin the real estate sector across China. Richard has extensive experience inall facets of transactional activity and in real estate development, assetacquisitions, finance, tax, corporate structures and investor relations. InMacquarie he had ultimate responsibility for staff and financial management. Richard Ding has been appointed General Counsel of THC. In this position,Richard has responsibility for all legal matters for THC. Prior to joining THC,Richard was General Counsel, and Director, Strategy & Corporate Transactions forglobal automotive supplier Visteon Corporation's Asia Pacific operations.Previously Richard was Managing Director of Concord Venture Capital Group, aleading Asia Pacific venture capital firm, gaining extensive experience withincorporate finance, mergers and acquisitions, and venture investment with a focuson cross-border transactions in or involving Asia Pacific and China. Rob Tincknell, who became Managing Director of THC in 2006, has been appointedDeputy Chairman of THC. He is also a Director of CREO. Rob Tincknell commented: "We are delighted to have made appointments of this calibre to support CREO'soperations in China. Both have experience and expertise in China and will provevaluable additions to the substantial resources that Treasury Holdings havealready committed here. Both Richard Barrett and myself will remain in Shanghaifull time, underlining the significance and focus we are bringing to ouroperations here." CREORay Horney Tel: + 44 (0) 1273 775 225Richard Barrett Tel: + 862 1 5385 8369Robert Tincknell Tel: + 862 1 5385 8369 Teather & Greenwood Tel: + 44 (0) 20 7426 7736Paul FinchamJonathan BecherRobert Naylor Bankside Consultants Ltd Tel: + 44 (0) 20 7367 8888Simon RothschildOliver Winters Murray ConsultantsElizabeth Headon Tel: + 353 1 498 0300 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
23rd Jun 20267:00 amRNSAppointment of Nominated Adviser /Corporate Broker
4th Jun 20267:00 amRNSPosting of 2025 Annual Report and Notice of AGM
28th May 20262:35 pmRNSHolding(s) in Company
22nd May 202610:11 amRNSResult of Placing
22nd May 20267:02 amRNSProposed Placing to raise approximately £5.5m
22nd May 20267:01 amRNSFY25 Final Results
22nd May 20267:00 amRNSProposed Sale of 49% Interest in Creo Medical SL
7th May 20267:00 amRNS-RMicroBlate™ Fine commercial update
5th May 20267:00 amRNS-RSpydrBlade™ Flex used in novel BEAM procedures
30th Apr 20267:00 amRNS-RKOL presentations on Creo Core Products at DDW
29th Apr 20267:00 amRNS-RUK private hospital use Speedboat for cancer case
22nd Apr 20267:00 amRNSPositive Q1 trading update
16th Apr 20267:00 amRNSDisposal and outsourcing of manufacturing
24th Feb 20267:00 amRNSAppointment of Joint Corporate Broker
20th Jan 20267:00 amRNSFY25 Trading Update
14th Jan 20267:00 amRNSAward of Shares under Share Incentive Plan
27th Oct 20257:00 amRNSNotice of Capital Markets Day
7th Oct 202511:37 amRNSCapital Markets Day update
22nd Sep 20257:00 amRNSUnaudited results for the six months ended 30 June
12th Sep 20253:14 pmRNSHolding(s) in Company
11th Sep 20257:00 amRNSNotice of Results
12th Aug 20254:56 pmRNSDirector/PDMR Share Dealing
4th Aug 20257:00 amRNS-RSpeedboat® patient testimonial
24th Jul 20257:00 amRNSAward of Shares under SIP and Director Dealings
21st Jul 20257:00 amRNSH1’25 Trading Update
10th Jul 20257:00 amRNS-RMicroBlate™ Flex begins lung tumour clinical study
9th Jul 20259:41 amRNSPDMR Options Revision
30th Jun 20257:00 amRNSChange of Nominated Adviser
26th Jun 202511:08 amRNSResult of AGM
26th Jun 20257:00 amRNSAGM Statement and Directorate Changes
11th Jun 20257:00 amRNS-RU.S. FDA clearance for SpydrBlade™ Flex
2nd Jun 20257:00 amRNSDirector/PDMR Shareholding
30th May 20257:00 amRNSPosting of AR&R and Notice of AGM
28th May 20257:00 amRNSUS Reimbursement milestone for Speedboat procedure
27th May 202512:48 pmRNSHolding(s) in Company
23rd May 20254:25 pmRNSHolding(s) in Company
22nd May 20257:00 amRNSDirectorate changes
19th May 20257:00 amRNSFinal Results
6th May 20257:00 amRNSNotice of investor presentations
15th Apr 20252:00 pmRNSNotice of Results
1st Apr 20259:34 amRNSHolding(s) in Company
31st Mar 202512:17 pmRNSHolding(s) in Company
26th Mar 20257:00 amRNSGrant of Options
20th Mar 20257:00 amRNS-RUK & EU Commercial launch of SpydrBlade™ Flex
6th Mar 20257:00 amRNSAppointment of Nominated Adviser and sole Broker
17th Feb 20257:00 amRNSFY24 Trading Update
12th Feb 202511:00 amRNSCompletion of sale of 51% interest in subsidiary
6th Feb 20259:00 amRNS-RFirst Welsh adopter of Speedboat® technology
3rd Feb 20253:00 pmRNSTotal Voting Rights
21st Jan 20257:00 amRNSAward of Shares under Share Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.